We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+30.89%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$331M
AUM Growth
+$38.2M
Cap. Flow
-$22.9M
Cap. Flow %
-6.93%
Top 10 Hldgs %
73.74%
Holding
44
New
9
Increased
8
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
2
AGEN
Agenus
AGEN
+$10M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.17M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.86M
5
ARWR icon
Arrowhead Research
ARWR
+$7.24M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$29.3M
2
INCY icon
Incyte
INCY
+$16.9M
3
KITE
Kite Pharma, Inc.
KITE
+$14.3M
4
SSRG
SYMMETRY SURGICAL INC COMMON STK
SSRG
+$12.1M
5
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$6.25M

Sector Composition

Rank Sector Weight
1 Healthcare 95.25%
2 Miscellaneous 4.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$31.7B
$64.3M 19.43%
948,286
+115,737
+14% +$8.17M
AVXS
2
DELISTED
AveXis, Inc. Common Stock
AVXS
$34M 10.29%
825,980
+349,613
+73% +$13.3M
AGEN
3
Agenus
AGEN
$345M
$29.7M 8.99%
211,017
+87,252
+70% +$10M
LJPC
4
DELISTED
La Jolla Pharmaceutical Company
LJPC
$27.8M 8.41%
1,170,151
-5,995
-0.5% -$113K
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.51B
$18.5M 5.6%
4,204,579
+1,967,513
+88% +$7.86M
INCY icon
6
Incyte
INCY
$25.2B
$18M 5.45%
191,151
-201,085
-51% -$16.9M
ACHN
7
DELISTED
Achillion Pharmaceuticals
ACHN
$17.9M 5.41%
2,208,749
-215,387
-9% -$1.83M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$11.9M 3.6%
2,026,894
– –
BMY icon
9
Bristol-Myers Squibb
BMY
$136B
$11.3M 3.42%
209,701
– –
GLD icon
10
SPDR Gold Trust
GLD
$149B
$10.4M 3.15%
83,000
– –
ATRA icon
11
Atara Biotherapeutics
ATRA
$92.3M
$9.8M 2.96%
18,325
-310
-2% -$168K
ARWR icon
12
Arrowhead Research
ARWR
$12B
$8.21M 2.48%
+1,116,777
New +$7.24M
HRTX icon
13
Heron Therapeutics
HRTX
$62M
$6.66M 2.01%
+386,787
New +$7.18M
VIVE
14
DELISTED
VIVEVE MED INC
VIVE
$6.06M 1.83%
839
+24
+3% +$159K
BLUE
15
DELISTED
bluebird bio
BLUE
$5.95M 1.8%
6,773
-40,475
-86% -$29.3M
CORI
16
DELISTED
Corium International, Inc.
CORI
$5.89M 1.78%
1,045,747
+192,786
+23% +$969K
IVTY
17
DELISTED
Invuity, Inc
IVTY
$5.39M 1.63%
392,838
+166,796
+74% +$1.98M
CLDX icon
18
Celldex Therapeutics
CLDX
$3.07B
$5.02M 1.52%
82,878
-1,404
-2% -$87.4K
MDCO
19
DELISTED
Medicines Co
MDCO
$4.64M 1.4%
+123,000
New +$4.64M
OMER icon
20
Omeros
OMER
$1.35B
$4.27M 1.29%
383,012
-143,776
-27% -$1.64M
TCMD icon
21
Tactile Systems Technology
TCMD
$525M
$4.26M 1.29%
+227,599
New +$3.49M
JO
22
DELISTED
iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038
JO
$4.02M 1.21%
180,500
+36,300
+25% +$792K
RGNX icon
23
Regenxbio
RGNX
$638M
$3.35M 1.01%
238,740
-4,044
-2% -$44.6K
OXFD
24
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.96M 0.9%
+235,900
New +$2.37M
FPRX
25
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.31M 0.7%
44,044
-657
-1% -$31.4K
1
2

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q3 2016 Portfolio in Review

As of Q3 2016, RTW Investments held 44 positions worth $331M, up 13% from $293M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

RTW Investments withdrew a net $22.9M in Q3 2016, closing 8 positions and reducing 11 holdings. Its most notable exit was Kite Pharma, Inc., an estimated $14.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 88% a quarter earlier, followed by Miscellaneous.

Against the trend, RTW Investments opened a new position in Arrowhead Research worth $8.21M.

  • RTW Investments's largest Q3 2016 buy was Arrowhead Research: 1,116,777 shares worth $8.21M.
  • RTW Investments added most to AveXis, Inc. Common Stock in Q3 2016, an estimated $13.3M increase.
  • RTW Investments's biggest Q3 2016 reduction was bluebird bio, cutting an estimated $29.3M.
  • RTW Investments fully exited Kite Pharma, Inc. in Q3 2016, selling an estimated $14.3M.
  • RTW Investments's ten largest holdings make up 74% of its $331M portfolio in Q3 2016.
  • RTW Investments opened 9 new positions and closed 8 in Q3 2016.
  • RTW Investments's portfolio value rose 13% quarter-over-quarter to $331M.

Based on RTW Investments's 13F filing for Q3 2016, filed 14 Nov 2016.